Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers
Authors:
Preprint
Abstract
YAP and TAZ, key effectors of the Hippo pathway, are frequently hyperactivated in cancer, where they drive tumor progression and resistance to therapy. Their oncogenic activity relies on interaction with TEAD transcription factors, making the TEAD-YAP/TAZ complex an attractive therapeutic target. Using translational mouse models, we demonstrate that sustained systemic YAP/TAZ depletion leads to severe side effects. However, even transient YAP/TAZ inhibition alone is sufficient to suppress tumor growth in advanced stages. Mechanistically, YAP/TAZ activity promotes T cell exclusion from the tumors by inducing target genes involved in tissue remodeling. Consequentially, YAP/TAZ inhibition induces immune infiltration, but the infiltrating T cells rapidly become exhausted. Combining YAP/TAZ inhibition with immune checkpoint blockade (ICB) overcomes this exhaustion and sensitizes previously resistant tumors to immunotherapy.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (EY 120/4-1)
- Deutsche Forschungsgemeinschaft (EY 120/9-1)
- Deutsche Forschungsgemeinschaft (EY 120/10-1)
- Deutsche Forschungsgemeinschaft (SFB1292 subproject TP21N)
- Bundesministerium für Forschung, Technologie und Raumfahrt (16GW0271K)
- Leibniz Collaborative Excellence (K398/2021)
This publication has 28 references indexed in Scilit:
- Inference and analysis of cell-cell communication using CellChatNature Communications, 2021
- ATAC-seq footprinting unravels kinetics of transcription factor binding during zygotic genome activationNature Communications, 2020
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerCell Reports, 2018
- Hippo pathway deficiency reverses systolic heart failure after infarctionNature, 2017
- Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAPCancer Cell, 2014
- Yap1 Acts Downstream of α-Catenin to Control Epidermal ProliferationCell, 2011
- Elucidation of a Universal Size-Control Mechanism in Drosophila and MammalsCell, 2007
- Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic ApproachCell, 2006
- Cre recombinase‐mediated gene targeting of mesenchymal cellsGenesis, 2004